Lenacapavir HIV Prevention: Gilead’s Stra...

By João L. Carapinha

July 10, 2025

Gilead Sciences has finalized a strategic partnership with the Global Fund. The agreement aims to supply lenacapavir HIV prevention, a twice-yearly inject...
Talquetamab Multiple Myeloma: Impact, Evidence, and Policy Considerations
Impending Net Drug Price Transparency Regulation in the U.S.
Pharmaceutical Pricing Issues: Beyond Overpricing and Profit Motives
NICE Rejects Donanemab: Treatment Cost-Effectiveness
Pfizer Conference Insights: Analyzing Bourla’s Strategic Vision Amid Po...
Revitalizing Innovation: The Impact of UK Medicine Payment Rates
Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...
Another GLP-1 Drug Access Model: Will a Co-Pay Cap Revolutionize Affordability?
The Impact of MFN Pricing on the U.S. Biosimilar Market
Biosimilars Price Competition: Impact on U.S. Pharmaceutical Pricing and Mark...
MFN Drug Pricing Targets: Lowering U.S. Drug Costs Through International Alig...